TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12120937
Drug: Premature-delayed vaccination
Normalized name: adenovirus type 4 vaccine live Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premature-delayed vaccination (first dose when weight of 2,000 g reached)
Study: 12120937
Drug: Premature vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premature vaccination (first dose within 24 h of birth)
Study: 12120937
Drug: Full-term vaccination
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-term vaccination (first dose within 24 h of birth)
Study: 65040
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bleomycin and Radiotherapy
Study: 15372414
Drug: 4,000 U
Normalized name: vitamin D3 14,000 UNT Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,000 U subcutaneous epoetin alfa
Study: 15372414
Drug: 10,000 U
Normalized name: Erwinaze 10,000 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 U subcutaneous epoetin alfa
Study: 9274470
Drug: Antibiotics (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (300 mg metronidazole, 500 mg amoxycillin, 250 mg clarithromycin, each given four times daily for two weeks)
Study: 9274470
Drug: Antibiotics with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics with H pylori clearance
Study: 9274470
Drug: Antibiotics with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics with H pylori eradication
Study: 21115933
Drug: finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: finasteride 5 mg/day
Study: 21115933
Drug: dutasteride 4
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dutasteride 4 mg/day
Study: 2872803
Drug: Terazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (1 to 40 mg daily, administered alone or in combination with other antihypertensive agents)
Study: 24553033
Drug: Group BFM:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group BFM: 0.0625% bupivacaine + 2 μg/ml fentanyl + 2 mg morphine in 15 mL saline
Study: 24553033
Drug: Group BF:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group BF: 0.1% bupivacaine + 2 μg/mL fentanyl in 15 mL saline
Study: 20498395
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5) plus Pegylated liposomal Doxorubicin (30 mg/m²) every 4 weeks
Study: 20498395
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m²) every 3 weeks
Study: 15099916
Drug: Cyclazocine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclazocine (0.4 mg)
Study: 15099916
Drug: Cyclazocine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclazocine (0.8 mg)
Study: 15099916
Drug: Hydromorphone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (5 mg)
Study: 15099916
Drug: Hydromorphone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (15 mg)
Study: 15099916
Drug: Cyclazocine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclazocine (0.2 mg)
Study: 12185409
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg IV)
Study: 9824875
Drug: Clozapine titration
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine titration (6-8 weeks)
Study: 9824875
Drug: Typical antipsychotic
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical antipsychotic drugs (APD)
Study: 7663868
Drug: Intra-articular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular morphine sulfate 1 mg in normal saline 10 ml
Study: 7663868
Drug: Intra-articular 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular 0.5% bupivacaine 10 ml
Study: 2680154
Drug: PQ 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: PQ 750 mg with NQ 25 mg
Study: 2680154
Drug: PYR 600
Normalized name: pyrilamine maleate 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: PYR 600 mg with NQ 25 mg
Study: 2680154
Drug: PYR 800
Normalized name: Pyrilamine
DrugBank: Mepyramine (DB06691)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PYR 800 mg with NQ 40 mg
Study: 2680154
Drug: PYR 800
Normalized name: Pyrilamine
DrugBank: Mepyramine (DB06691)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PYR 800 mg with NQ 80 mg
Study: 2680154
Drug: PYR 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PYR 1,200 mg alone
Study: 25566874
Drug: Self-management intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management intervention (self-monitoring for the first week of each month and individualized treatment self-titration schedule)
Study: 24165817
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) of propofol with alfentanil
Study: 24165817
Drug: Manually controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually controlled infusion (MCI) of propofol with alfentanil
Study: 19364980
Drug: Doxycycline (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (50, 100, or 300 mg/d for 2 weeks)
Study: 15705641
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg every 12 h
Study: 14998986
Drug: Quinupristin-dalfopristin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinupristin-dalfopristin 7.5 mg/kg every 8 h
Study: 9455715
Drug: Carbopol matrix
Normalized name: Carbopol 981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbopol matrix tablet with normal diet
Study: 9455715
Drug: Carbopol matrix
Normalized name: Carbopol 981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbopol matrix tablet with high fat diet
Study: 9455715
Drug: Carbopol matrix
Normalized name: Carbopol 981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbopol matrix tablet with high fat/high protein diet
Study: 9455715
Drug: Lipid matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid matrix tablet with fasting condition
Study: 9455715
Drug: Lipid matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid matrix tablet with normal diet
Study: 9455715
Drug: Lipid matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid matrix tablet with high fat diet
Study: 9455715
Drug: Lipid matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid matrix tablet with high fat/high protein diet
Study: 30590573
Drug: Paracetamol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1000 mg) taken 1 hour prior to pain rating
Study: 27341326
Drug: BalanceWear Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BalanceWear Therapy (BWT), weighted orthotic (WG), worn for 4 hours per day for 5 days
Study: 27341326
Drug: Sham BalanceWear
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham BalanceWear Therapy (SWG), sham-weighted orthotic, worn for 4 hours per day for 5 days
Study: 25622201
Drug: self-help cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: self-help cognitive-behavioral therapy (shCBT) + sibutramine
Study: 25622201
Drug: self-help cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: self-help cognitive-behavioral therapy (shCBT) + placebo
Study: 14653129
Drug: recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant growth hormone (rhGH) therapy (4 U per day for 7 days)
Study: 14653129
Drug: human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: human albumin (10 g every other day for 3 times)
Study: 9124393
Drug: L-NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (3 mg/kg bolus infusion over 5 min, followed by 50 µg x kg(‐1) x min(‐1) over 120 min)
Study: 9124393
Drug: L-arginine (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (17 mg x kg(‐1) x min(‐1) over 30 min)
Study: 8310886
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg post-evening meal (pem)
Study: 30477864
Drug: Crocetin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocetin 7.5 mg/day
Study: 26653113
Drug: NK3 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK3 receptor antagonist ESN364 (3-180 mg single dose)
Study: 26653113
Drug: NK3 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK3 receptor antagonist ESN364 (20, 60, or 180 mg daily for 10 days)
Study: 26653113
Drug: NK3 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK3 receptor antagonist ESN364 (20, 60, or 180 mg daily for 21 days)
Study: 25516360
Drug: Donepezil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (10 mg/d for 3 months) with psychosocial intervention
Study: 16382306
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (Lantus) subcutaneously at a dosage equal to the average of insulin/day administered in the preceding days of AN
Study: 12593425
Drug: Tc‐99m MAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tc‐99m MAA injection in cirrhosis patients
Study: 9650539
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch delivering 11 mg/day
Study: 9650539
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch delivering 22 mg/day
Study: 9650539
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch delivering 44 mg/day
Study: 8589208
Drug: Argatroban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (2.5 mg/h for the first 48 hours, then 10 mg infused over 3 hours twice a day on days 3-7)
Study: 2572899
Drug: Daily treatment
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment with isoniazid (400 mg) and rifampicin (600 mg)
Study: 2572899
Drug: Twice-weekly treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly treatment with isoniazid (900 mg) and rifampicin (600 mg)
Study: 19508250
Drug: SRP&DOXY (scaling
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP&DOXY (scaling and root planing with 14% doxycycline gel applied subgingivally)
Study: 7830728
Drug: Lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (40 mg twice daily)
Study: 8185726
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (600 mg daily)
Study: 21910937
Drug: Daily rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rTMS (5 days/week for 4 weeks, 20 treatments in total)
Study: 21910937
Drug: Spaced rTMS
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spaced rTMS (3 days/week for 6 weeks, 18 treatments in total)
Study: 21910937
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Daily and Spaced rTMS)
Study: 12468134
Drug: Estradot transdermal
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradot transdermal oestrogen patch (50 microg/day)
Study: 12468134
Drug: Menorest transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menorest transdermal oestrogen patch (50 microg/day)
Study: 10479159
Drug: WR 238605
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR 238605 (Tafenoquine) 300 mg daily for 7 days (Group A)
Study: 10479159
Drug: WR 238605
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR 238605 (Tafenoquine) 500 mg daily for 3 days (Group B)
Study: 10479159
Drug: WR 238605
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR 238605 (Tafenoquine) 1 dose of 500 mg (Group C)
Study: 1720759
Drug: Alternating weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Alternating weekly chemotherapy regimen including Doxorubicin, vincristine, cyclophosphamide, bleomycin, intrathecal methotrexate and cytarabine, Methotrexate with leucovorin rescue, Ifosfamide with mesna, etoposide, and intrathecal methotrexate and cytarabine
Study: 1720759
Drug: One additional
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One additional cycle or three monthly CHOP (consolidation treatment)
Study: 6819029
Drug: Protein energy
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein energy supplement (energy and vitamins with 5-10% of energy from milk protein)
Study: 6819029
Drug: Vitamins only
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins only (a multivitamin sachet daily containing vitamins A, B, C, and D)
Study: 26931763
Drug: On-site urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-site urine drug screening tests (OS-UDS) with training for GPs and supply of tests at medical offices.
Study: 26931763
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (standard medical strategy for assessing drug use).
Study: 20563294
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment targets for LDL-C ≤70 mg/dL and systolic BP ≤115 mmHg
Study: 20563294
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment targets for LDL-C ≤100 mg/dL and systolic BP ≤130 mmHg
Study: 12102278
Drug: Weekly dose
Normalized name: XPOVIO 60 MG Weekly Dose Carton Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly dose of 100 mg of leflunomide
Study: 12102278
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of leflunomide
Study: 9695721
Drug: Basiliximab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (40 mg total intravenous dose) in addition to baseline dual immunosuppression (cyclosporine and steroids)
Study: 2673516
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of semisynthetic human insulin (Novolin) providing a 70:30 ratio of NPH to regular insulin
Study: 2673516
Drug: Variable ratio
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable ratio of semisynthetic human insulin, regular and NPH (control group)
Study: 1151293
Drug: nurse‐proctocol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: nurse‐proctocol treatment plan
Study: 1151293
Drug: physician treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: physician treatment plan
Study: 30395904
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg once daily during and up to 3 months after RT
Study: 25724455
Drug: Infliximab dosing
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab dosing based on therapeutic drug monitoring (TCs)
Study: 25724455
Drug: Infliximab dosing
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab dosing based on clinical features
Study: 25724455
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation to reach TCs of 3-7 μg/mL
Study: 25724455
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction for TCs >7 μg/mL
Study: 24382088
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity treatment
Study: 24382088
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity treatment
Study: 21992849
Drug: Low-dose human
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose human atrial natriuretic peptide
Study: 7783109
Drug: Enalapril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10-40 mg once daily)
Study: 2083405
Drug: Allergen-antibody complexes
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen-antibody complexes
Study: 23869828
Drug: Pre-heated infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-heated infusion solutions (colloids and crystalloids)
Study: 21803933
Drug: tDCS combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS combined with constraint-induced movement therapy (CIMT)
Study: 19699854
Drug: SCH 530348
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 530348 2.5 mg daily
Study: 10516738
Drug: Irbesartan/HCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ combination therapy (starting with irbesartan 75 mg/HCTZ 12.5 mg once daily, titrated to irbesartan 150 mg/HCTZ 12.5 mg, then to irbesartan 300 mg/HCTZ 25 mg if necessary)
Study: 2371577
Drug: N-acetyl-beta-glucosaminidase (NAG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-beta-glucosaminidase (NAG) excretion measurement in patients with upper urinary tract infections
Study: 2371577
Drug: N-acetyl-beta-glucosaminidase (NAG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-beta-glucosaminidase (NAG) excretion measurement in patients with lower urinary tract infections
Study: 2371577
Drug: N-acetyl-beta-glucosaminidase (NAG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-beta-glucosaminidase (NAG) excretion measurement in patients with lower urinary tract symptoms and underlying diseases
Study: 7247360
Drug: Trimethoprim (TMP)
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim (TMP) 200 mg twice daily
Study: 7247360
Drug: Sulfamethoxazole-trimethoprim (SMX-TMP)
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfamethoxazole-trimethoprim (SMX-TMP) 800/160 mg twice daily
Study: 28744102
Drug: Generic alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic alendronate sodium tablets (70 mg)
Study: 28744102
Drug: Fosamax® tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosamax® tablets (70 mg) - first dose
Study: 28744102
Drug: Fosamax® tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosamax® tablets (70 mg) - second dose
Study: 25083010
Drug: Professionally administered
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professionally administered CBT‐I (PCBT‐I; n = 81)
Study: 25083010
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (CTL; n = 81)
Study: 17356993
Drug: Buprenorphine/naloxone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone with 20 minutes counseling and weekly visits
Study: 17356993
Drug: Buprenorphine/naloxone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone with 45 minutes counseling and thrice weekly visits
Study: 17356993
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and ancillary services
Study: 10429837
Drug: Zanamivir 10
Normalized name: Zanamivir 10 mg/mL solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir 10 mg from the Diskhaler
Study: 10429837
Drug: Zanamivir 10
Normalized name: Zanamivir 10 mg/mL solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir 10 mg from the prototype device
Study: 10429837
Drug: Overall inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall inhalation of zanamivir
Study: 7591715
Drug: Intravenous betahistine
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous betahistine (57, 114, and 285 micrograms i.d.)
Study: 7591715
Drug: Oral betahistine
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral betahistine plus cetirizine and cimetidine
Study: 7591715
Drug: Oral betahistine
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral betahistine alone
Study: 2124446
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug for a mean period of 6 weeks (range: 3‐12 weeks)
Study: 29173856
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fixed retainers and Essix
Study: 23990233
Drug: Adenosine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (2 mg + 2 mg) administered during PCI
Study: 22250038
Drug: Formoterol (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (24 µg)
Study: 22250038
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 µg)
Study: 19583040
Drug: Stannous fluoride
Normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stannous fluoride solution (8%)
Study: 17325272
Drug: Lipid-lowering agents
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering agents (LLA)
Study: 17325272
Drug: Lipid-lowering agents
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering agents (LLA) indicated
Study: 16960636
Drug: Infrared therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared therapy (IR therapy)
Study: 14691360
Drug: Individual cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive‐behavioral family‐based therapy (CBFT)
Study: 14691360
Drug: Group cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive‐behavioral family‐based therapy (CBFT)
Study: 11054434
Drug: Renal function-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal function-based dosing